Literature DB >> 19370366

Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study.

Fedor N Novikov1, Viktor S Stroylov, Oleg V Stroganov, Val Kulkov, Ghermes G Chilov.   

Abstract

Poly-(ADP-ribose)-polymerase (PARP) is a promising anti-cancer target as it plays a crucial role in the cellular reparation and survival mechanisms. However, the development of a robust and cost effective experimental technique to screen PARP inhibitors is still a scientific challenge owing to the difficulties in quantitative detection of the enzyme activity. In this work we demonstrate that the computational chemistry tools including molecular docking and scoring can perform on par with the experimental studies in assessing binding constants and in the recovery of active compounds in virtual screening. Using the recently introduced Lead Finder software we were able to dock a set of 142 well characterized PARP inhibitors and obtain a good correlation between the calculated and experimentally measured binding energies with the rmsd of 1.67 kcal mol(-1). Additionally, fine-tuning of the energy scaling coefficients within the Lead Finder scoring function has further decreased rmsd to the value of 0.88 kcal mol(-1). Moreover, we were able to reproduce the selectivity of ligand binding between the two isoforms of the enzyme-PARP1 and PARP2-suggesting that the Lead Finder software can be used to design isoform-selective inhibitors of PARP. An impressive enrichment was obtained in the virtual screening experiment, in which the mentioned set of PARP inhibitors was mixed with a commercial library of 300,000 compounds. We also demonstrate that the virtual screening performance can be significantly improved by an additional structural filtration of the docked ligand poses through detection of the crucial hydrogen bonding interactions with the enzyme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370366     DOI: 10.1007/s00894-009-0497-y

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  22 in total

1.  Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.

Authors:  E Perkins; D Sun; A Nguyen; S Tulac; M Francesco; H Tavana; H Nguyen; S Tugendreich; P Barthmaier; J Couto; E Yeh; S Thode; K Jarnagin; A Jain; D Morgans; T Melese
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.

Authors:  Janice A Brown; Ravi B Marala
Journal:  J Pharmacol Toxicol Methods       Date:  2002 May-Jun       Impact factor: 1.950

3.  Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.

Authors:  G Costantino; A Macchiarulo; E Camaioni; R Pellicciari
Journal:  J Med Chem       Date:  2001-11-08       Impact factor: 7.446

4.  An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications.

Authors:  P Decker; E A Miranda; G de Murcia; S Muller
Journal:  Clin Cancer Res       Date:  1999-05       Impact factor: 12.531

5.  PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.

Authors:  J C Amé; V Rolli; V Schreiber; C Niedergang; F Apiou; P Decker; S Muller; T Höger; J Ménissier-de Murcia; G de Murcia
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

6.  Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.

Authors:  Junya Ishida; Hirofumi Yamamoto; Yoshiyuki Kido; Kazunori Kamijo; Kenji Murano; Hiroshi Miyake; Mitsuru Ohkubo; Takayoshi Kinoshita; Masaichi Warizaya; Akinori Iwashita; Kayoko Mihara; Nobuya Matsuoka; Kouji Hattori
Journal:  Bioorg Med Chem       Date:  2005-11-08       Impact factor: 3.641

7.  Novel poly(ADP-ribose) polymerase-1 inhibitors.

Authors:  Derek Dunn; Jean Husten; Mark A Ator; Sankar Chatterjee
Journal:  Bioorg Med Chem Lett       Date:  2006-10-10       Impact factor: 2.823

Review 8.  The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.

Authors:  Paul O Hassa; Michael O Hottiger
Journal:  Front Biosci       Date:  2008-01-01

9.  An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.

Authors:  Karson S Putt; Paul J Hergenrother
Journal:  Anal Biochem       Date:  2004-03-01       Impact factor: 3.365

10.  Identification of potential active-site residues in the human poly(ADP-ribose) polymerase.

Authors:  F Simonin; O Poch; M Delarue; G de Murcia
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

View more
  5 in total

1.  The 1.8 Å cholix toxin crystal structure in complex with NAD+ and evidence for a new kinetic model.

Authors:  Robert J Fieldhouse; René Jørgensen; Miguel R Lugo; A Rod Merrill
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

2.  Lead Finder docking and virtual screening evaluation with Astex and DUD test sets.

Authors:  Fedor N Novikov; Viktor S Stroylov; Alexey A Zeifman; Oleg V Stroganov; Val Kulkov; Ghermes G Chilov
Journal:  J Comput Aided Mol Des       Date:  2012-05-09       Impact factor: 3.686

3.  Identification of New Structural Fragments for the Design of Lactate Dehydrogenase A Inhibitors.

Authors:  D K Nilov; A V Kulikov; E A Prokhorova; V K Švedas
Journal:  Acta Naturae       Date:  2016 Jul-Sep       Impact factor: 1.845

4.  Structure Modeling of Human Tyrosyl-DNA Phosphodiesterase 1 and Screening for Its Inhibitors.

Authors:  I V Gushchina; D K Nilov; A L Zakharenko; O I Lavrik; V K Švedas
Journal:  Acta Naturae       Date:  2017 Apr-Jun       Impact factor: 1.845

5.  Virtual interactomics of proteins from biochemical standpoint.

Authors:  Jaroslav Kubrycht; Karel Sigler; Pavel Souček
Journal:  Mol Biol Int       Date:  2012-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.